Gene therapy and High-Tech glasses aim to restore sight in blinding eye disease
NCT ID NCT03326336
Summary
This early-stage study is testing the safety of a new gene therapy called GS030 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive a single injection into the eye and then use special stimulating glasses. The main goal is to see if the treatment is safe and tolerable, while also checking if it might help improve vision or daily tasks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SYNDROMIC RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts
Paris, 75012, France
-
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, United Kingdom
-
UPMC Eye Center
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.